BofA/Merrill Lynch Starts Aimmune Therapeutics (AIMT) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Credit Suisse Starts Aimmune Therapeutics (AIMT) at Outperform
August 31, 2015 7:12 AM EDTCredit Suisse initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Outperform rating and a price target of $44.00.
Analyst V. Divan commented, "We see AIMT as one of the leaders in developing treatments to help manage life-threatening food allergies, with... More
Piper Jaffray Starts Aimmune Therapeutics (AIMT) at Overweight
August 31, 2015 6:27 AM EDTPiper Jaffray initiates coverage on Aimmune Therapeutics (NASDAQ: AIMT) with a Overweight rating and a price target of $35.00, leading data in peanut allergy.
Analyst Charles Duncan commented, "Aimmune is leveraging its broadly applicable oral immunotherapy (OIT) platform to develop proprietary products aimed at protecting patients... More
